Talphera Seeks FDA Approval to Close NEPHRO CRRT Trial Early
Talphera has submitted a briefing document to the FDA requesting an early close of its NEPHRO CRRT study enrollment after surpassing 80% statistical power.
Talphera Inc. has submitted a briefing document to the U.S. Food and Drug Administration requesting a Sprint Meeting to discuss closing enrollment in its pivotal NEPHRO CRRT clinical study, based on the number of patients enrolled as of December 31, 2026, the company disclosed in its third-quarter 2026 financial results and business update.
The move signals a potentially significant milestone for the drug developer. The company said its NEPHRO study has exceeded 80% statistical power for the primary endpoint, a threshold that can support a request to close a trial earlier than originally planned without undermining the scientific validity of the results.
Read more NICB Flags Top Insurance Fraud Trends to Watch in 2026 →
Sprint Meetings are a formal FDA mechanism that allows sponsors to seek rapid, targeted guidance on specific development questions. By requesting this type of meeting, Talphera is signaling confidence in the strength of the data accumulated to date and looking to accelerate the trial's path toward a potential regulatory submission.
An early close of enrollment, if granted, would reduce the time and cost associated with completing the pivotal study, potentially bringing the company closer to a New Drug Application filing. Investors and analysts tracking rare-disease and critical-care drug development will likely watch the FDA's response to the Sprint Meeting request as a key near-term catalyst for the company.
Continue reading at Earnings for the full third-quarter financial results and additional business update details.